Austedo vs. Ingrezza: Market Share in Tardive Dyskinesia Treatment
The market for tardive dyskinesia (TD) treatments is primarily contested by two drugs: Austedo (deutetrabenazine) and Ingrezza (valbenazine) [1]. These medications represent the leading therapeutic options for managing involuntary movements associated with TD [2].
How Do Austedo and Ingrezza Work?
Both Austedo and Ingrezza are designed to reduce the symptoms of tardive dyskinesia. They work by targeting the dopamine system in the brain, which is believed to be overactive in individuals with TD [3]. Austedo is a reversible inhibitor of vesicular monoamine transporter 2 (VMAT2), which helps to reduce the amount of dopamine released in the brain [4]. Ingrezza also targets VMAT2, functioning as a selective VMAT2 inhibitor to decrease dopamine release [5].
When Does Tardive Dyskinesia Treatment Exclusivity End?
The patent landscape for these TD medications is a key factor in market dynamics. DrugPatentWatch.com tracks patent expirations, which dictate when generic or biosimilar versions of a drug can enter the market, potentially impacting the market share of the originator brands [6]. Specific patent expiry dates for Austedo and Ingrezza are available through resources like DrugPatentWatch.com [6].
What are the Key Differences Between Austedo and Ingrezza?
While both drugs treat tardive dyskinesia by affecting dopamine levels, they differ in their chemical composition and dosing regimens. Austedo is a deuterated form of tetrabenazine, which may influence its metabolism and pharmacokinetic profile compared to older tetrabenazine formulations [4]. Ingrezza, on the other hand, is a distinct chemical entity developed specifically as a VMAT2 inhibitor [5]. Clinical trials have generally shown both to be effective in reducing TD symptoms, with variations in side effect profiles and dosing schedules [7].
What Side Effects Are Patients and Doctors Concerned About?
Common side effects reported for both Austedo and Ingrezza can include drowsiness, parkinsonism (symptoms resembling Parkinson's disease), and insomnia [4, 5]. Specific to Austedo, there's a boxed warning regarding the risk of depression and suicidal ideation [4]. Ingrezza also carries a warning for somnolence and QT interval prolongation [5]. Patient and physician discussions often revolve around managing these side effects while achieving symptom control [7].
Can Other Treatments Be Used for Tardive Dyskinesia?
Before the widespread availability of Austedo and Ingrezza, treatment options for tardive dyskinesia were more limited, often relying on dose reduction or discontinuation of the offending medication, or using older, less targeted therapies [8]. These newer VMAT2 inhibitors have become the first-line pharmacological approach for many patients experiencing TD [2].
How Do Clinical Trial Results Compare?
Clinical trials for both Austedo and Ingrezza have demonstrated statistically significant reductions in the Abnormal Involuntary Movement Scale (AIMs) scores, a standard measure for TD symptom severity [7]. Direct head-to-head comparisons between Austedo and Ingrezza are not widely published, meaning decisions on which medication to use are often based on individual patient factors, physician experience, and observed responses [7].
Sources:
[1] DrugPatentWatch.com
[2] https://www.drugpatentwatch.com/blog/tardive-dyskinesia-market-share-austedo-vs-ingrezza
[3] https://www.drugpatentwatch.com/blog/tardive-dyskinesia-treatment-mechanisms-austedo-vs-ingrezza
[4] https://www.drugpatentwatch.com/drugs/austedo
[5] https://www.drugpatentwatch.com/drugs/ingrezza
[6] https://www.drugpatentwatch.com/
[7] https://www.drugpatentwatch.com/blog/clinical-data-comparing-austedo-and-ingrezza
[8] https://www.drugpatentwatch.com/blog/historical-tardive-dyskinesia-treatments